The BRD4‐targeting drug JQ1 was found to suppress proliferation in KU812 cells and primary leukemic cells in the majority of patients with chronic phase CML. This evidence concerns the gene BRD4 and chronic myelogenous leukemia, BCR-ABL1 positive.